Lilly(US:LLY) GLP1减重宝典·2025-11-23 04:24Group 1 - The core point of the article discusses the restructuring and downsizing of Eli Lilly's immunology business in China, focusing on optimizing regional business layouts and promoting personnel mobility across business lines [4][5][6] - The personnel adjustments will primarily direct employees towards diabetes and Alzheimer's disease-related business lines, indicating a strategic shift in focus [5] - This restructuring may impact the domestic immunology market landscape, warranting ongoing attention to industry developments [6] Group 2 - As of November 20, 2025, there are eight pharmaceutical companies in the A-share market with a market capitalization exceeding 100 billion yuan, collectively valued at over 1.7 trillion yuan [8] - Eli Lilly's market capitalization surpasses 1 trillion USD (approximately 71,116 billion yuan), which is about 4.18 times the total market capitalization of all A-share companies valued over 100 billion yuan, equating to approximately 17.63 times that of Heng Rui Medicine [8]